Lipum AB (publ)FNSE Lipum AB Stock Report

Lipum AB engages in the research and development of novel anti-inflammatory drugs. The company is headquartered in Umea, Vasterbottens. The company went IPO on 2021-04-22. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.